SIG -2%: surprisingly tough finish to the day for Sigma who substantially upgraded guidance for their FY22 result due out at the end of the month. The pharmaceutical wholesaler upgraded EBITDA guidance to 10-15% growth for the year against previous guidance of -10% as strong demand for COVID RATs helped turnaround performance into the January year end. Despite the big shift in guidance, the result will still be weighed on by further cost issues from the rollout of their ERP software designed to help pharmacies manage stock and workers. It does say a lot about the new system that it’s taken 4 weeks from the end of the financial year to notice a 20% swing in performance, and the upgrade is largely one-off given the nature of the demand for RATs.
scroll
Question asked
Question asked
Performance update for March, stocks that drove returns & our current positioning
Close
Friday 26th April – ASX200 -101pts, Newmont (NEM), Resmed (RMD) & Super Retail (SUL)
Close
Market Matters Research Lead Shawn Hickman with David Koch
Close
MM is not excited about SIG ~50c
Add To Hit List
Related Q&A
Sigma and Chemist Warehouse merger
What are MM’s thoughts on Sigma (SIG)?
Relevant suggested news and content from the site
Video
WATCH
Performance update for March, stocks that drove returns & our current positioning
Recorded Tuesday 9th April
Podcast
LISTEN
Friday 26th April – ASX200 -101pts, Newmont (NEM), Resmed (RMD) & Super Retail (SUL)
Daily Podcast Direct from the Desk
Video
WATCH
Market Matters Research Lead Shawn Hickman with David Koch
Recorded Monday 25th March
Members only
UNLOCK MARKET MATTERS NOW
Take a free trial.
No payment details required.